Pembrolizumab
-
KEYTRUDA® and Padcev® Combination Improves Survival and Response in Muscle-Invasive Bladder Cancer
Merck’s KEYNOTE-905 (EV-303) trial showed positive results for muscle-invasive bladder cancer (MIBC) patients ineligible for cisplatin-based chemotherapy. The study combined KEYTRUDA (pembrolizumab) and Padcev (enfortumab vedotin-ejfv) before and after surgery, demonstrating statistically significant and clinically meaningful improvement in event-free survival (EFS), overall survival (OS), and pathologic complete response (pCR) compared to surgery alone. This represents the first systemic therapy to improve survival in this population, potentially establishing a new standard of care. The treatment’s safety profile was consistent with existing data.
